Sex-oriented perspectives in immunopharmacology
Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issue...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Andrea Cignarella [verfasserIn] Elisabetta Vegeto [verfasserIn] Chiara Bolego [verfasserIn] Luigia Trabace [verfasserIn] Lucia Conti [verfasserIn] Elena Ortona [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Pharmacological Research ; 197(2023), Seite 106956- volume:197 ; year:2023 ; pages:106956- |
|---|
| Links: |
|---|
| DOI / URN: |
10.1016/j.phrs.2023.106956 |
|---|
| Katalog-ID: |
DOAJ092957331 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ092957331 | ||
| 003 | DE-627 | ||
| 005 | 20240413012529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2023.106956 |2 doi | |
| 035 | |a (DE-627)DOAJ092957331 | ||
| 035 | |a (DE-599)DOAJd7d784b802834855939bfe896b0885bd | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Andrea Cignarella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sex-oriented perspectives in immunopharmacology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines. | ||
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Immune system modulating agents | |
| 650 | 4 | |a Sex and gender pharmacology | |
| 650 | 4 | |a Teplizumab: TNF inhibitors | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Elisabetta Vegeto |e verfasserin |4 aut | |
| 700 | 0 | |a Chiara Bolego |e verfasserin |4 aut | |
| 700 | 0 | |a Luigia Trabace |e verfasserin |4 aut | |
| 700 | 0 | |a Lucia Conti |e verfasserin |4 aut | |
| 700 | 0 | |a Elena Ortona |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Pharmacological Research |g 197(2023), Seite 106956- |
| 773 | 1 | 8 | |g volume:197 |g year:2023 |g pages:106956- |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.phrs.2023.106956 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d7d784b802834855939bfe896b0885bd |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1043661823003122 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1096-1186 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 197 |j 2023 |h 106956- | ||
| author_variant |
a c ac e v ev c b cb l t lt l c lc e o eo |
|---|---|
| matchkey_str |
andreacignarellaelisabettavegetochiarabo:2023----:eoineprpcieiimn |
| hierarchy_sort_str |
2023 |
| callnumber-subject-code |
RM |
| publishDate |
2023 |
| allfields |
10.1016/j.phrs.2023.106956 doi (DE-627)DOAJ092957331 (DE-599)DOAJd7d784b802834855939bfe896b0885bd DE-627 ger DE-627 rakwb eng RM1-950 Andrea Cignarella verfasserin aut Sex-oriented perspectives in immunopharmacology 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines. Immune checkpoint inhibitors Immune system modulating agents Sex and gender pharmacology Teplizumab: TNF inhibitors Therapeutics. Pharmacology Elisabetta Vegeto verfasserin aut Chiara Bolego verfasserin aut Luigia Trabace verfasserin aut Lucia Conti verfasserin aut Elena Ortona verfasserin aut In Pharmacological Research 197(2023), Seite 106956- volume:197 year:2023 pages:106956- https://doi.org/10.1016/j.phrs.2023.106956 kostenfrei https://doaj.org/article/d7d784b802834855939bfe896b0885bd kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661823003122 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 197 2023 106956- |
| spelling |
10.1016/j.phrs.2023.106956 doi (DE-627)DOAJ092957331 (DE-599)DOAJd7d784b802834855939bfe896b0885bd DE-627 ger DE-627 rakwb eng RM1-950 Andrea Cignarella verfasserin aut Sex-oriented perspectives in immunopharmacology 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines. Immune checkpoint inhibitors Immune system modulating agents Sex and gender pharmacology Teplizumab: TNF inhibitors Therapeutics. Pharmacology Elisabetta Vegeto verfasserin aut Chiara Bolego verfasserin aut Luigia Trabace verfasserin aut Lucia Conti verfasserin aut Elena Ortona verfasserin aut In Pharmacological Research 197(2023), Seite 106956- volume:197 year:2023 pages:106956- https://doi.org/10.1016/j.phrs.2023.106956 kostenfrei https://doaj.org/article/d7d784b802834855939bfe896b0885bd kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661823003122 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 197 2023 106956- |
| allfields_unstemmed |
10.1016/j.phrs.2023.106956 doi (DE-627)DOAJ092957331 (DE-599)DOAJd7d784b802834855939bfe896b0885bd DE-627 ger DE-627 rakwb eng RM1-950 Andrea Cignarella verfasserin aut Sex-oriented perspectives in immunopharmacology 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines. Immune checkpoint inhibitors Immune system modulating agents Sex and gender pharmacology Teplizumab: TNF inhibitors Therapeutics. Pharmacology Elisabetta Vegeto verfasserin aut Chiara Bolego verfasserin aut Luigia Trabace verfasserin aut Lucia Conti verfasserin aut Elena Ortona verfasserin aut In Pharmacological Research 197(2023), Seite 106956- volume:197 year:2023 pages:106956- https://doi.org/10.1016/j.phrs.2023.106956 kostenfrei https://doaj.org/article/d7d784b802834855939bfe896b0885bd kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661823003122 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 197 2023 106956- |
| allfieldsGer |
10.1016/j.phrs.2023.106956 doi (DE-627)DOAJ092957331 (DE-599)DOAJd7d784b802834855939bfe896b0885bd DE-627 ger DE-627 rakwb eng RM1-950 Andrea Cignarella verfasserin aut Sex-oriented perspectives in immunopharmacology 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines. Immune checkpoint inhibitors Immune system modulating agents Sex and gender pharmacology Teplizumab: TNF inhibitors Therapeutics. Pharmacology Elisabetta Vegeto verfasserin aut Chiara Bolego verfasserin aut Luigia Trabace verfasserin aut Lucia Conti verfasserin aut Elena Ortona verfasserin aut In Pharmacological Research 197(2023), Seite 106956- volume:197 year:2023 pages:106956- https://doi.org/10.1016/j.phrs.2023.106956 kostenfrei https://doaj.org/article/d7d784b802834855939bfe896b0885bd kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661823003122 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 197 2023 106956- |
| allfieldsSound |
10.1016/j.phrs.2023.106956 doi (DE-627)DOAJ092957331 (DE-599)DOAJd7d784b802834855939bfe896b0885bd DE-627 ger DE-627 rakwb eng RM1-950 Andrea Cignarella verfasserin aut Sex-oriented perspectives in immunopharmacology 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines. Immune checkpoint inhibitors Immune system modulating agents Sex and gender pharmacology Teplizumab: TNF inhibitors Therapeutics. Pharmacology Elisabetta Vegeto verfasserin aut Chiara Bolego verfasserin aut Luigia Trabace verfasserin aut Lucia Conti verfasserin aut Elena Ortona verfasserin aut In Pharmacological Research 197(2023), Seite 106956- volume:197 year:2023 pages:106956- https://doi.org/10.1016/j.phrs.2023.106956 kostenfrei https://doaj.org/article/d7d784b802834855939bfe896b0885bd kostenfrei http://www.sciencedirect.com/science/article/pii/S1043661823003122 kostenfrei https://doaj.org/toc/1096-1186 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 197 2023 106956- |
| language |
English |
| source |
In Pharmacological Research 197(2023), Seite 106956- volume:197 year:2023 pages:106956- |
| sourceStr |
In Pharmacological Research 197(2023), Seite 106956- volume:197 year:2023 pages:106956- |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Immune checkpoint inhibitors Immune system modulating agents Sex and gender pharmacology Teplizumab: TNF inhibitors Therapeutics. Pharmacology |
| isfreeaccess_bool |
true |
| container_title |
Pharmacological Research |
| authorswithroles_txt_mv |
Andrea Cignarella @@aut@@ Elisabetta Vegeto @@aut@@ Chiara Bolego @@aut@@ Luigia Trabace @@aut@@ Lucia Conti @@aut@@ Elena Ortona @@aut@@ |
| publishDateDaySort_date |
2023-01-01T00:00:00Z |
| id |
DOAJ092957331 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ092957331</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413012529.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phrs.2023.106956</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ092957331</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd7d784b802834855939bfe896b0885bd</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Andrea Cignarella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sex-oriented perspectives in immunopharmacology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune checkpoint inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune system modulating agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sex and gender pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Teplizumab: TNF inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabetta Vegeto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Bolego</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luigia Trabace</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucia Conti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elena Ortona</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmacological Research</subfield><subfield code="g">197(2023), Seite 106956-</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:197</subfield><subfield code="g">year:2023</subfield><subfield code="g">pages:106956-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phrs.2023.106956</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d7d784b802834855939bfe896b0885bd</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1043661823003122</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1096-1186</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">197</subfield><subfield code="j">2023</subfield><subfield code="h">106956-</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Andrea Cignarella |
| spellingShingle |
Andrea Cignarella misc RM1-950 misc Immune checkpoint inhibitors misc Immune system modulating agents misc Sex and gender pharmacology misc Teplizumab: TNF inhibitors misc Therapeutics. Pharmacology Sex-oriented perspectives in immunopharmacology |
| authorStr |
Andrea Cignarella |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RM1-950 |
| illustrated |
Not Illustrated |
| topic_title |
RM1-950 Sex-oriented perspectives in immunopharmacology Immune checkpoint inhibitors Immune system modulating agents Sex and gender pharmacology Teplizumab: TNF inhibitors |
| topic |
misc RM1-950 misc Immune checkpoint inhibitors misc Immune system modulating agents misc Sex and gender pharmacology misc Teplizumab: TNF inhibitors misc Therapeutics. Pharmacology |
| topic_unstemmed |
misc RM1-950 misc Immune checkpoint inhibitors misc Immune system modulating agents misc Sex and gender pharmacology misc Teplizumab: TNF inhibitors misc Therapeutics. Pharmacology |
| topic_browse |
misc RM1-950 misc Immune checkpoint inhibitors misc Immune system modulating agents misc Sex and gender pharmacology misc Teplizumab: TNF inhibitors misc Therapeutics. Pharmacology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Pharmacological Research |
| hierarchy_top_title |
Pharmacological Research |
| isfreeaccess_txt |
true |
| title |
Sex-oriented perspectives in immunopharmacology |
| ctrlnum |
(DE-627)DOAJ092957331 (DE-599)DOAJd7d784b802834855939bfe896b0885bd |
| title_full |
Sex-oriented perspectives in immunopharmacology |
| author_sort |
Andrea Cignarella |
| journal |
Pharmacological Research |
| journalStr |
Pharmacological Research |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| container_start_page |
106956 |
| author_browse |
Andrea Cignarella Elisabetta Vegeto Chiara Bolego Luigia Trabace Lucia Conti Elena Ortona |
| container_volume |
197 |
| class |
RM1-950 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Andrea Cignarella |
| doi_str_mv |
10.1016/j.phrs.2023.106956 |
| author2-role |
verfasserin |
| title_sort |
sex-oriented perspectives in immunopharmacology |
| callnumber |
RM1-950 |
| title_auth |
Sex-oriented perspectives in immunopharmacology |
| abstract |
Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines. |
| abstractGer |
Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines. |
| abstract_unstemmed |
Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| title_short |
Sex-oriented perspectives in immunopharmacology |
| url |
https://doi.org/10.1016/j.phrs.2023.106956 https://doaj.org/article/d7d784b802834855939bfe896b0885bd http://www.sciencedirect.com/science/article/pii/S1043661823003122 https://doaj.org/toc/1096-1186 |
| remote_bool |
true |
| author2 |
Elisabetta Vegeto Chiara Bolego Luigia Trabace Lucia Conti Elena Ortona |
| author2Str |
Elisabetta Vegeto Chiara Bolego Luigia Trabace Lucia Conti Elena Ortona |
| callnumber-subject |
RM - Therapeutics and Pharmacology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.phrs.2023.106956 |
| callnumber-a |
RM1-950 |
| up_date |
2024-07-03T14:36:09.207Z |
| _version_ |
1803568932935696384 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ092957331</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413012529.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phrs.2023.106956</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ092957331</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd7d784b802834855939bfe896b0885bd</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Andrea Cignarella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sex-oriented perspectives in immunopharmacology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Several immunopharmacological agents are effective in the treatment of cancer and immune-mediated conditions, with a favorable impact on life expectancy and clinical outcomes for a large number of patients. Nevertheless, response variation and undesirable effects of these drugs represent major issues, and overall efficacy remains unpredictable. Males and females show a distinct difference in immune system responses, with females generally mounting stronger responses to a variety of stimuli. Therefore, exploring sex differences in the efficacy and safety of immunopharmacological agents would strengthen the practice of precision medicine. As a pharmacological target highlight, programmed cell death 1 ligand 1 (PD-L1) is the first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1). The PD-L1/PD-1 crosstalk plays an important role in the immune response and is relevant in cancer, infectious and autoimmune disease. Sex differences in the response to immune checkpoint inhibitors are well documented, with male patients responding better than female patients. Similarly, higher efficacy of and adherence to tumor necrosis factor inhibitors in chronic inflammatory conditions including rheumatoid arthritis and Crohn’s disease have been reported in male patients. The pharmacological basis of sex-specific responses to immune system modulating drugs is actively investigated in other settings such as stroke and type 1 diabetes. Advances in therapeutics targeting the endothelium could soon be wielded against autoimmunity and metabolic disorders. Based on the established sexual dimorphism in immune-related pathophysiology and disease presentation, sex-specific immunopharmacological protocols should be integrated into clinical guidelines.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune checkpoint inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune system modulating agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sex and gender pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Teplizumab: TNF inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabetta Vegeto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Bolego</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luigia Trabace</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucia Conti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elena Ortona</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmacological Research</subfield><subfield code="g">197(2023), Seite 106956-</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:197</subfield><subfield code="g">year:2023</subfield><subfield code="g">pages:106956-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phrs.2023.106956</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d7d784b802834855939bfe896b0885bd</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1043661823003122</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1096-1186</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">197</subfield><subfield code="j">2023</subfield><subfield code="h">106956-</subfield></datafield></record></collection>
|
| score |
7.398242 |